GlassScriptPhysician profile
Elizabeth Beazley
NPI 1730718990
$1,127.14
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $427.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.06 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $147.77 | 2021 | |
| Abbvie INC. | $117.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.56 | 2021 | |
| Genentech USA, INC. | $27.55 | 2021-2022 | |
| Lilly USA, LLC | $25.89 | 2021 | |
| Eisai INC. | $23.23 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.90 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.84 | 2021 | |
| Novo Nordisk INC | $16.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.21 | 2022 | |
| Ibsa Pharma INC. | $14.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.74 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12.14 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Beazley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.